Políticas Médicas
Las políticas médicas son documentos que definen el reconocimiento de cubierta para tecnologías, procedimientos y tratamientos. Las declaraciones de necesidad médica en las políticas, sobre si una tecnología, procedimiento, tratamiento, suplido, equipo, medicamento u otro servicio mejora el resultado en la salud de la población para la cual dicha tecnología o tratamiento fue diseñado se basan en evidencia científica, estudios clínicos y opiniones profesionales de nuestros proveedores y de las organizaciones médicas reconocidas.
Cada documento desplegado en este sitio Web se provee con propósitos informativos solamente y no es una autorización, explicación de beneficios o un contrato. El recibir beneficios está sujeto a la satisfacción de todos los términos y condiciones de la cubierta. La tecnología médica cambia constantemente y nos reservamos el derecho de revisar y actualizar nuestras políticas periódicamente.
| ID | Título | Última Revisión | Siguiente Revisión | Descripción | Acceso |
|---|---|---|---|---|---|
| 04.001.024 | Services For Intra-Uterine Device Management | Nov 09, 2022 | Policy Archived | The intrauterine device (iud) is the most commonly used method of long-acting reversible contraception... | Ver |
| 04.002.001 | TRATAMIENTO DEL SÍNDROME DE TRANSFUSIÓN DE GEMELO A GEMELO UTILIZANDO AMNIOREDUC | Dec 13, 2017 | Policy Archived | ... | Ver |
| 04.002.002 | Cirugía fetal para malformaciones congénitas diagnosticadas en periodo perinatal | Dec 08, 2022 | Policy Archived | Fetal surgery is used for specific congenital abnormalities associated with a poor postnatal prognosis.... | Ver |
| 04.002.004 | GENDER AFFIRMING SURGERY | Sep 25, 2025 | Sep 20, 2026 | This policy addresses gender affirming surgery (also known as sex affirmation surgery, gender or sex... | Ver |
| 04.002.005 | Infertility Treatment | Oct 26, 2023 | Policy Archived | A person is considered infertile if he or she is unable to conceive or produce conception after 1 year of... | Ver |
| 05.001.002 | Renagel | May 10, 2016 | Policy Archived | ... | Ver |
| 05.001.004 | Botulinum Toxin | Nov 06, 2025 | Nov 20, 2026 | Botulinum is a family of toxins produced by the anaerobic organism clostridia botulinum. multiple... | Ver |
| 05.001.005 | Human Growth Hormone | Nov 17, 2025 | Nov 20, 2026 | Recombinant human growth hormone (gh) is approved by the u.s. food and drug administration (fda) for various... | Ver |
| 05.001.006 | Recombinant And Autologous Platelet-Derived Growth Factors For Wound Healing And Other Non‒Orthopedic Conditions | Feb 13, 2025 | Feb 20, 2026 | The use of blood-derived growth factors, including recombinant platelet-derived growth factors (pdgfs) and... | Ver |
| 05.001.007 | Hepatitis-C crónica (Peg-Intron & Rebetol) | May 16, 2016 | Policy Archived | ... | Ver |
| 05.001.008 | Immunoglobulin Therapy | Nov 17, 2025 | Nov 20, 2026 | Immunoglobulins are derived from human donor plasma and used to treat an array of disorders, including... | Ver |
| 05.001.009 | Infliximab | Sep 25, 2025 | Sep 20, 2026 | Infliximab (remicade®) is a tumor necrosis factor α (tnf-α) blocking agent approved by the... | Ver |
| 05.001.010 | Immune Prophylaxis For Respiratory Syncytial Virus | Sep 11, 2024 | Policy Archived | Respiratory syncytial virus (rsv) is the most common cause of lower respiratory tract infections in children.... | Ver |
| 05.001.011 | TOCOLISIS CON TERBUTALINA INTRAVENOSA O SUBCUTANEO | Aug 07, 2019 | Policy Archived | Of... | Ver |
| 05.001.012 | (Trastuzumab) Herceptin | Sep 25, 2025 | Sep 20, 2026 | In certain cancers, the human epidermal growth factor receptor 2 (her2) gene is amplified and overexpressed.... | Ver |
| 05.001.014 | Intravenous Anesthetics For The Treatment Of Chronic Pain And Psychiatric Disorders | Dec 03, 2024 | Dec 20, 2025 | Intravenous (iv) infusion of lidocaine or ketamine has been investigated for the treatment of migraine and... | Ver |
| 05.001.015 | Advanced Therapies For Pharmacologic Treatment Of Pulmonary Hypertension | Dec 20, 2024 | Dec 20, 2025 | Pulmonary hypertension (ph) is a chronic, progressive condition characterized by abnormally high pulmonary... | Ver |
| 05.001.016 | Uses Of Monoclonal Antibodies For The Treatment Of Non-Hodgkin Lymphoma | Dec 04, 2024 | Policy Archived | Monoclonal antibodies targeted to cancer-associated antigens have been approved by the u.s. food and drug... | Ver |
| 05.001.017 | Bevacizumab | Sep 25, 2025 | Sep 20, 2026 | Bevacizumab is a humanized monoclonal antibody directed against vascular endothelial growth factor a... | Ver |
| 05.001.019 | ABATACEPT (ORENCIA) | Dec 31, 1969 | Sep 20, 2026 | From the decade of 1990 the advances in molecular biology have shown new approaches to the treatment for... | Ver |
